FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1993517814> ?p ?o ?g. }

• W1993517814 endingPage "657" @default.
• W1993517814 startingPage "657" @default.
• W1993517814 abstract "To the Editor We have read the summary of the National Cancer Institute/National Institutes of Diabetes and Digestive and Kidney Diseases–sponsored workshop on Pancreatitis, Diabetes, and Pancreatic Cancer held in June 2013, written by Andersen et al,1 with considerable interest. Novo Nordisk was as industry representative invited by the organizers to present the current evidence around pancreatic cancer and type 3c diabetes in the liraglutide development program. We commend the organizers for having organized a conference of high scientific merit and for thoroughly summarizing the proceedings in this article. There are a few statements in the section concerning the Novo Nordisk data that should be clarified. The publication states that the incidence rate of acute pancreatitis in type 2 diabetes is 0.55 to 1.37 cases per 1000 patient-years. As quoted in our presentation, based on work by several authors,2–5 the incidence rate can be estimated to be 0.5 to 5.6 cases per 1000 patient-years, that is, up to 3 times higher than in a population of individuals without diabetes. These estimates place the incidence rate of acute pancreatitis observed in the clinical development program of liraglutide in type 2 diabetes within the range seen in the background type 2 diabetes population.6 Based on available data, Novo Nordisk can neither confirm nor exclude a causal relationship for liraglutide and pancreatitis because of the low number of adjudicated events reported in our trials. The labeling for Victoza (Novo Nordisk A/S, Bagsvaerd, Denmark) includes a warning for pancreatitis and describes the symptoms of this condition to assist clinicians in their decision making. Importantly, based on the totality of information available to Novo Nordisk, there is no evidence that liraglutide increases the risk of pancreas cancer in humans or induces dysplasia or precancerous lesions in animal models. Using a new monoclonal antibody for immunohistochemistry, we detected the GLP-1 receptor (GLP-1R) in the non–human primate pancreas. The GLP-1R was predominantly localized in beta cells with a markedly weaker expression in acinar cells. Pancreatic ductal epithelial cells did not express GLP-1R, in agreement with results using in situ ligand binding in samples from pancreatic ductal adenocarcinomas.7 To generate more definite evidence to assess the association between liraglutide administration and pancreatic disease, Novo Nordisk is conducting a large-scale, double-blind cardiovascular outcome study (LEADER; NCT01179048) that will prospectively evaluate the overall safety of liraglutide. The trial has enrolled 9340 patients with type 2 diabetes. Adjudication of all adverse reactions related to pancreatitis and any neoplasm is an integral part of the protocol.8 While Novo Nordisk also is pursuing prospectively designed pharmacovigilance studies,9 randomized, controlled, large, long-duration trials with independent adjudication provide the most objective way to evaluate infrequent adverse effects, as also mentioned by Drucker recently.10 The LEADER study will be reported in 2016. Alan Charles Moses, MD Global Chief Medical Office, Research & Development, Novo Nordisk A/S, Bagsværd Denmark Lotte Bjerre Knudsen, BSc Diabetes Research Unit, Research & Development, Novo Nordisk A/S, Måløv Denmark Claus Bo Svendsen, MD, PhD Global Medical Affairs GLP-1 Diabetes, Novo Nordisk A/S, Denmark [email protected] Conflicts of Interest and Source of Funding: All authors are employees of Novo Nordisk A/S and hold employee shares in the company. The work was funded by Novo Nordisk A/S." @default.
• W1993517814 created "2016-06-24" @default.
• W1993517814 creator A5038941136 @default.
• W1993517814 creator A5058457879 @default.
• W1993517814 creator A5088627727 @default.
• W1993517814 date "2014-05-01" @default.
• W1993517814 modified "2023-09-26" @default.
• W1993517814 title "Comment on Andersen et al, Pancreatitis–Diabetes–Pancreatic Cancer" @default.
• W1993517814 cites W2050984323 @default.
• W1993517814 cites W2053646449 @default.
• W1993517814 cites W2057913111 @default.
• W1993517814 cites W2061738696 @default.
• W1993517814 cites W2107824623 @default.
• W1993517814 cites W2110333911 @default.
• W1993517814 cites W2140004965 @default.
• W1993517814 cites W2144028372 @default.
• W1993517814 cites W2164535707 @default.
• W1993517814 doi "https://doi.org/10.1097/mpa.0000000000000037" @default.
• W1993517814 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4206353" @default.
• W1993517814 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24713674" @default.
• W1993517814 hasPublicationYear "2014" @default.
• W1993517814 type Work @default.
• W1993517814 sameAs 1993517814 @default.
• W1993517814 citedByCount "2" @default.
• W1993517814 countsByYear W19935178142015 @default.
• W1993517814 countsByYear W19935178142019 @default.
• W1993517814 crossrefType "journal-article" @default.
• W1993517814 hasAuthorship W1993517814A5038941136 @default.
• W1993517814 hasAuthorship W1993517814A5058457879 @default.
• W1993517814 hasAuthorship W1993517814A5088627727 @default.
• W1993517814 hasBestOaLocation W19935178142 @default.
• W1993517814 hasConcept C120665830 @default.
• W1993517814 hasConcept C121332964 @default.
• W1993517814 hasConcept C121608353 @default.
• W1993517814 hasConcept C126322002 @default.
• W1993517814 hasConcept C134018914 @default.
• W1993517814 hasConcept C177713679 @default.
• W1993517814 hasConcept C187212893 @default.
• W1993517814 hasConcept C2775967933 @default.
• W1993517814 hasConcept C2776670229 @default.
• W1993517814 hasConcept C2777180221 @default.
• W1993517814 hasConcept C2780210213 @default.
• W1993517814 hasConcept C2781308992 @default.
• W1993517814 hasConcept C2908647359 @default.
• W1993517814 hasConcept C512399662 @default.
• W1993517814 hasConcept C555293320 @default.
• W1993517814 hasConcept C61434518 @default.
• W1993517814 hasConcept C61511704 @default.
• W1993517814 hasConcept C71924100 @default.
• W1993517814 hasConcept C99454951 @default.
• W1993517814 hasConceptScore W1993517814C120665830 @default.
• W1993517814 hasConceptScore W1993517814C121332964 @default.
• W1993517814 hasConceptScore W1993517814C121608353 @default.
• W1993517814 hasConceptScore W1993517814C126322002 @default.
• W1993517814 hasConceptScore W1993517814C134018914 @default.
• W1993517814 hasConceptScore W1993517814C177713679 @default.
• W1993517814 hasConceptScore W1993517814C187212893 @default.
• W1993517814 hasConceptScore W1993517814C2775967933 @default.
• W1993517814 hasConceptScore W1993517814C2776670229 @default.
• W1993517814 hasConceptScore W1993517814C2777180221 @default.
• W1993517814 hasConceptScore W1993517814C2780210213 @default.
• W1993517814 hasConceptScore W1993517814C2781308992 @default.
• W1993517814 hasConceptScore W1993517814C2908647359 @default.
• W1993517814 hasConceptScore W1993517814C512399662 @default.
• W1993517814 hasConceptScore W1993517814C555293320 @default.
• W1993517814 hasConceptScore W1993517814C61434518 @default.
• W1993517814 hasConceptScore W1993517814C61511704 @default.
• W1993517814 hasConceptScore W1993517814C71924100 @default.
• W1993517814 hasConceptScore W1993517814C99454951 @default.
• W1993517814 hasIssue "4" @default.
• W1993517814 hasLocation W19935178141 @default.
• W1993517814 hasLocation W19935178142 @default.
• W1993517814 hasLocation W19935178143 @default.
• W1993517814 hasLocation W19935178144 @default.
• W1993517814 hasOpenAccess W1993517814 @default.
• W1993517814 hasPrimaryLocation W19935178141 @default.
• W1993517814 hasRelatedWork W1998737455 @default.
• W1993517814 hasRelatedWork W2018216037 @default.
• W1993517814 hasRelatedWork W2055401600 @default.
• W1993517814 hasRelatedWork W2411835944 @default.
• W1993517814 hasRelatedWork W2895897325 @default.
• W1993517814 hasRelatedWork W2904604492 @default.
• W1993517814 hasRelatedWork W3031817754 @default.
• W1993517814 hasRelatedWork W3206407087 @default.
• W1993517814 hasRelatedWork W4288044049 @default.
• W1993517814 hasRelatedWork W4303685082 @default.
• W1993517814 hasVolume "43" @default.
• W1993517814 isParatext "false" @default.
• W1993517814 isRetracted "false" @default.
• W1993517814 magId "1993517814" @default.
• W1993517814 workType "article" @default.